Key result
Patients with nonfunctional adrenal incidentaloma had significantly higher irisin levels (17.58 vs 14.03 pg/mL) and lower nesfatin-1 levels (194.98 vs 303.48 pg/mL) compared to healthy controls.
Why the study?
To investigate irisin and nesfatin-1 levels and their relationship with cardiometabolic risk markers, including CIMT and EAT thickness, in patients with nonfunctional adrenal incidentaloma.
Are irisin and nesfatin-1 levels altered in patients with nonfunctional adrenal incidentaloma and associated with cardiometabolic risk markers?
Cross-Sectional (n=118)
No
Are irisin and nesfatin-1 levels altered in patients with nonfunctional adrenal incidentaloma and associated with cardiometabolic risk markers?
Absolute Event Rate: 17.58% vs 14.03%
p-value: p=<0.001
Irisin and nesfatin-1 may serve as novel biomarkers for predicting cardiometabolic risk, specifically increased CIMT and EAT thickness, in patients with nonfunctional adrenal incidentalomas.
Irisin and nesfatin-1 may mark subclinical atherosclerosis in NFAI; hypothesis-generating for prospective validation before clinical use.
Objective: In our study, we aimed to investigate the levels of irisin, nesfatin-1 and the relationship between levels of these relatively new molecules with cardiometabolic risk markers; carotid intima-media thickness (CIMT), epicardial adipose tissue (EAT) thickness in patients with nonfunctional adrenal incidentaloma (NFAI). Materials and Methods: Patients with NFAI (n=59) and age, sex and body mass index-matched healthy control subjects (n=59) were enrolled in this study. Serum glucose, insulin, C-reactive protein (CRP), lipid, irisin and nesfatin-1 levels and echocardiographic CIMT and EAT thickness measurements were performed in patients and controls. Results: 303.48 ± 200.78 pg/mL in the control group. A positive correlation was found between irisin and nesfatin-1 levels and CIMT and EAT thickness in the NFAI group. Conclusions: In our study, we found that irisin level was higher and nesfatin-1 level was lower in patients with NFAI, and both irisin and nesfatin-1 levels were associated with CIMT and EAT thickness in NFAI patients.
No takes yet. Share an insight, caveat, or question.
Mustafa Can (2022) conducted a cross-sectional in Nonfunctional adrenal incidentaloma (n=118). Nonfunctional adrenal incidentaloma vs. Healthy controls was evaluated on Serum irisin level (pg/mL) (p=<0.001). Patients with nonfunctional adrenal incidentaloma had significantly higher irisin levels (17.58 vs 14.03 pg/mL) and lower nesfatin-1 levels (194.98 vs 303.48 pg/mL) compared to healthy controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: